CTIM-34. PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIENTS WITH RELAPSED/REFRACTORY CNS LYMPHOMA TREATED WITH EMAVUSERTIB (CA-4948) AND IBRUTINIB COMBINATION: A SUBSET ANALYSIS OF TAKEAIM LYMPHOMA TRIAL

Authors: Madiha Iqbal, Han Tun, Erel Joffe, Christian Grommes, Grzegorz Nowakowski, Matthew Lunning, Radhakrishnan Ramchandren, Chia-Cheng Li, Wanying Zhao, Elizabeth Martinez, Reinhard von Roemeling, Robert Earhart, Meaghan McMahon, Iris Isufi, Lori Leslie, Allison Rosenthal

Published: 2022-11-14

DOI: 10.1093/neuonc/noac209.266

Source: Full article

CTIM-34. PRELIMINARY SAFETY AND EFFICACY DATA ON TWO PATIENTS WITH RELAPSED/REFRACTORY CNS LYMPHOMA TREATED WITH EMAVUSERTIB (CA-4948) AND IBRUTINIB COMBINATION: A SUBSET ANALYSIS OF TAKEAIM LYMPHOMA TRIAL

Abstract